Introduction
============

Pediatric ataxic gait and posture- assessment provides an important instrument to identify children and young adults with indisputable EOA ([@B3]; [@B19]). The availability of validated gait and posture- biomarkers in children is also important for the entry of high quality data in international EOA databases ([@B10]; [@B3]; [@B19]) and also for the evaluation of treatment ([@B23]), especially when the training of core-muscles is involved (such as by exergame-training) ([@B33]; [@B25]). In young, often disabled, EOA patients with limited concentration and physical endurance, optimally applicable gait and posture biomarkers are characterized as: non-invasive, quick and easy, compatible with adult parameters, reliable and also associated with a good construct validity ([@B26]; [@B24]). Until now, insight in the validity of clinically available gait and posture- biomarkers is incomplete. The SARA is described as a reliable, quickly assessable, and non-invasive rating scale for patients with ataxia ([@B27]). SARA scores consist of summed: gait and posture- (SARA~GAIT/POSTURE~ measuring gait, stance, sitting performances), kinetics (SARA~KINETIC~) and speech (SARA~SPEECH~) sub-scores ([@B27]). In EOA, we aimed to investigate the construct validity of the pediatric SARA~GAIT/POSTURE~ sub-scale scores.

For the investigation of the EOA SARA~GAIT/POSTURE~ construct validity, it is important to realize two points. First, it is important to realize that the SARA was originally designed and validated as a complete, total score in the domains of gait/posture, kinetics, and speech ([@B27]). However, under the assumption that the SARA sub-scale scores SARA~GAIT/POSTURE~ and SARA~KINETIC~ measure cerebellar functioning in different domains (i.e., vermis and anterior lobe and cerebellar hemispheres, respectively), we hypothesized that the SARA~GAIT/POSTURE~ sub-scale could be separately validated. Second, it is important to realize that the SARA was originally designed and validated in adult patients with AOA ([@B27]). However, due to the short clinical assessment time and good score reproducibility, the scale was soon applied in children too ([@B5], [@B4]; [@B15]; [@B22]). Before SARA scores can be analogously interpreted in AOA and EOA patients, it is thus important to take the effect of potential group differences into account. In comparison with the AOA patient group, EOA patients may reveal a large variety of disorders, with a heterogeneous phenotypic presentation and co-morbidity (such as myopathy and/or myoclonus). This explains why SARA score characteristics can differ between AOA and EOA patient groups ([@B29]; [@B30]; [@B5], [@B4]). For instance, in AOA patients, total SARA scores relate with ataxia as one single factor \[i.e., 'ataxia' ([@B27])\]. This is contrasted by total SARA scores in EOA patients, which are also attributed to: (1) pediatric age (i.e., cerebellar maturation; [@B17]; [@B29]; [@B5]), (2) comorbid muscle weakness \[in FA ([@B30])\], and (3) comorbid movement disorders ([@B4]).

In children and young adults with EOA, we thus aimed to investigate the construct validity of the SARA~GAIT/POSTURE~ sub-scale. Under the premise that parameters for SARA~GAIT/POSTURE~ would depend on the integrated cerebellar processing of visual, vestibular, and sensory signals of the limbs and trunk ([@B28]; [@B9]; [@B31]), SARA~GAIT/POSTURE~ sub-scales would be expected to correlate with biomarkers for dynamic and passive balance, such as: the scale for ASMK \[dynamic balance ([@B16])\] and the PBS (static balance; [@B13]). Additionally, we reasoned that clinically meaningful and effective SARA~GAIT/POSTURE~ sub-scores would relate with a validated, age-related classification system for functional motility in children, such as the GMFCS ([@B20]) -- the extended and revised version (E&R; [@B21]), which is originally designed for children with cerebral palsy. Furthermore, accurate kinematics for SARA~GAITPOSTURE~ performances would also correlate with biomarkers for kinetic-limb function, such as: SARA~KINETIC~ (upper and lower limbs) and AS \[upper limb kinetic scores ([@B32])\]. Finally, effective EOA SARA~GAIT/POSTURE~ scores would be expected to correlate with SARA~TOTAL~. Strong and significant correlations would underpin a good convergent validity of SARA~GAIT/POSTURE~ sub-scale scores. Absent influence by EOA co-morbidity factors (such as muscle weakness and/or myoclonus) on the scores would underpin sufficient discriminant validity of the SARA~GAIT/POSTURE~ sub-scale.

In the present study, we thus aimed to elucidate the construct validity and reliability of EOA SARA~GAIT/POSTURE~ sub-scale scores in children and young adults.

Materials and Methods {#s1}
=====================

The Medical Ethical Committee of the University Medical Center Groningen (UMCG), Netherlands, approved the study (METc 2011/165). According to the Dutch medical ethical law, both parents and children older than 12 years of age provided written informed consent. Children younger than 12 years of age provided assent. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the 'The Medical Ethical Committee of the University Medical Center Groningen (UMCG), Netherlands'. In the absence of preceding pediatric data for a power calculation, we performed a prospective, explorative study.

Patients
--------

Over a 5 year period (2011--2016), we have collected a complete cohort of EOA children that visited the pediatric neurology ward at UMCG ([@B4]). From this cohort, we included patients that fulfilled the criteria for "distinct ataxia," characterized by: EOA (initiation of ataxia before the 25th year of life) and unanimous recognition of ataxia as the main movement disorder by three independent pediatric neurologists and/or unanimous recognition of ataxia as part of the movement disorder by three independent pediatric neurologists *and* confirmation of the ataxic phenotype by the OMIM database^[1](#fn01){ref-type="fn"}^. Patients were excluded when they were unable to understand the required motor function tasks for the present study.

We included 28 EOA patients \[median age 15.5 (range: 6--34) years\]. The response rate was 100%. In 24/28 (86%) patients, ataxia was independently recognized as the main movement disorder by all three pediatric neurologists. The other 4 of 28 (14%) patients were included on basis of unanimous phenotypic ataxia recognition (primary or secondary features) *and* diagnostic confirmation that ataxia is involved according to the OMIM database^[1](#fn01){ref-type="fn"}^. Underlying metabolic or genetic diagnoses (*n* = 24/28) included: FA (*n* = 8), GOSR2-mutation (*n* = 4), ataxia with vitamin E deficiency (AVED; *n* = 2), CACNA1A-mutation (*n* = 2), Ataxia Telangiectasia (*n* = 1), Joubert syndrome type 23 (*n* = 1), Kearns Sayre syndrome (KSS; *n* = 1), MHBD-deficiency (*n* = 1), NARP-mutation (*n* = 1), Niemann--Pick type C (*n* = 1), Poretti Bolthauser syndrome (*n* = 1), and SCA5 (*n* = 1). The remaining four patients remained undiagnosed, despite whole exome sequencing. We assigned patients to 'myopathic' or 'myoclonic' EOA subgroups, when myopathy or myoclonus was described in the medical records as major comorbid EOA pathology *and* when myopathic or myoclonic features are phenotypically described in the OMIM database^1^. The 'myopathic' co-morbidity subgroup (EOA~MY\ OPATHIC~) involved 11 patients with FA (*n* = 8); KSS (*n* = 1); MHBD (*n* = 1); and NARP (*n* = 1) gene-mutations. The 'myoclonic' co-morbidity subgroup (EOA~MY\ OCLONIC~) involved four GOSR2 patients with spontaneous, multifocal myoclonus and action-induced enhancement, at the upper extremities, face and lower extremities ([@B34]). In all four EOA~MY\ OCLONIC~ patients, the medical records described clinical presence of comorbid myoclonus, which was also assessable during videotaped motor task performances (in 3 of 4 patients by 2 of 3 observers and in 1 patient by 1 of 3 observers). The remaining 'other' subgroup involved 13 patients, with neither 'myopathic' nor 'myoclonic' co-morbidity. In all patients, we reported the presence of secondary movement disorder features when at least 2 of 3 independent observers had assessed the same secondary feature, in accordance with the clinical phenotype. For patient characteristics, see **Table [1](#T1){ref-type="table"}**.

###### 

Patient characteristics.

                                    Age                EOA onset   EOA duration^\#^   Ambulant *n* (%)   2^nd^MD features video 2/3 obs; *n* (%)   Disease co-morbidity                                                                                                                                 Medicationˆ
  --------------------------------- ------------------ ----------- ------------------ ------------------ ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Total group (*n* = 28)^\$^        15.5 (6--34)       3 (0--11)   11 (3--25)         19 (68)                                                                                                                                                                                                           
  EOA~MY\ OPATHIC~ (*n* = 11)^\$^   17 (8--27)^ns^     4 (1--11)   7 (3--25)^ns^      4 (36)                                                       Hypertr cardiomyo (*n* = 6) Tachycardia (*n* = 2) Scoliosis (*n* = 2) Insulin deficiency (*n* = 1) AV-block (*n* = 1) Hypoparathyroidism (*n* = 1)   Idebenone (*n* = 5) Amiodaron (*n* = 1) Baclofen (*n* = 1) Magnesium (*n* = 1) Carbamazepine (*n* = 1)
  EOA~MY\ OCL~ (*n* = 4)            15 (6--25)^ns^     3 (1--3)    13 (3--22)^ns^     4 (100)            3 (75) Myoclonus                          Refractory epilepsy (*n* = 3)                                                                                                                        Valproic acid (*n* = 2) Levetiracetam (*n* = 2) Clonazepam (*n* = 3) Clobazam (*n* = 1) Topiramate (*n* = 1)
  EOA~OTHER~ (*n* = 13)             15 (8--34)         2 (0--11)   13.5 (8--23)       11 (85)            2 (15) Dystonia 2 (15) Chorea             IgA-deficiency (*n* = 1)                                                                                                                             Miglustat (*n* = 1) Sultiame (*n* = 1) Levetiracetam (*n* = 2) Valproaic acid (*n* = 1) Clonazepam (*n* = 1) Dipiperon (*n* = 1) Melatonin (*n* = 1) Concerta (*n* = 1)
  EOA~NON-MOY\ P~ (*n* = 17)        15 (6--34)^ns^     2 (0--11)   13.5 (3--23)^ns^   15 (88)                                                                                                                                                                                                           
  EOA~NON-MY\ OCL~ (*n* = 24)       15.5 (8--34)^ns^   3 (0--11)   11 (3--25)^ns^     15 (63)                                                                                                                                                                                                           

EOA, early onset ataxia; EOA onset and duration: median value (range); \# = scores are normally distributed; ambulant: number (%) ambulant patients; 2

nd

MD features video 2/3 obs = number (%) of secondary movement disorder features recognized by all 2 of the 3 observes; Medicationˆ = medication with published side effects on motor function; Hypertr cardiomyo, hypertrophic cardiomyopathy; \$ = data about disease onset and disease duration missing in 1 patient; EOA
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Assessments
-----------

In pediatric EOA patients, we investigated the SARA~GAIT/POSTURE~ construct validity by determining the: (1) inter-observer reliability, (2) convergent validity, and (3) discriminant validity.

### Inter-Observer Reliability

For the inter-observer reliability, we determined the Interclass Correlation Coefficient (ICC) of the SARA~GAIT/POSTURE~ video-ratings by three independent pediatric neurologists, according to the official SARA guidelines ([@B27]).

### Convergent Validity

For convergent validity, we correlated SARA~GAIT/POSTURE~ \[i.e., summed gait, stance, and sitting sub-scale scores ([@B27]\] with other rating scale scores for coordinated motor function, including ASMK \[dynamic balance ([@B16])\]; PBS \[static balance ([@B13])\]; GMFCS-E&R ([@B20], [@B21]), Dutch version^[2](#fn02){ref-type="fn"}^; SARA~KINETIC~ (kinetic function of upper and lower limbs) ([@B27]); AS (kinetic function of the upper limbs ([@B32]) and, finally also SARA~TOTAL~ \[summed ataxia scores in gait/posture, kinetic, and speech domains ([@B27])\]. To prevent unnecessary test burden and exhaustion of the patient, we planned investigations during successive hospital visits for clinical reasons. For latent time intervals between tests, see Supplementary Table [I](#SM1){ref-type="supplementary-material"}.

For information about SARA, AMSK, PBS, GMFCS-E&R, and AS testing, see Appendix B. The ASMK ([@B16]) and GMFCS ([@B21]) data were compiled from patient records and interviews. The PBS ([@B13]) scores were provided by one independent investigator, blinded for the results of the other test scores. In children, the reliability of this method was shown to be very high (ICC.997) ([@B14]).

### Discriminant Validity

For discriminant validity, we determined the potentially confounding influence by comorbid EOA factors, consisting of (1) myopathic muscle weakness and (2) myoclonus on the SARA~GAIT/POSTURE~ scores. We assessed MF by hand held dynamometry (CITEC; C.I.T. Technics, Haren, Groningen, Netherlands) ([@B2]). We determined summed total muscle force (MF~TOTAL~), upper extremity muscle force (MF~UE~), lower extremity muscle force (MF~LE~), and proximal muscle force (MF~PROX~). For detailed information of the tested muscles per item, see Appendix B. As the normality of pediatric MF depends on age, weight and sex, we expressed outcomes as Z-scores from the corrected normal values ([@B1]).

As 'ataxia' and/or 'myoclonus' could theoretically prohibit accurate muscle activation and/or MF assessment, we controlled whether paretic measurements (Z-scores \< -2 SD) were consistent with MU abnormalities of the same muscles. MU images (of the biceps, rectus femoris, and tibial anterior muscles) were obtained in accordance with a standard protocol and settings ([@B30]; [@B6]). Two MU experts independently classified MU images as: 'myopathic,' 'neuropathic,' 'combined' (i.e., myopathic and neuropathic) or 'none' (in absence of myopathic or neuropathic abnormalities). In a previous publication, we have shown the reliability of this method ([@B7]). Myopathic abnormalities are characterized by homogeneously increased MU density and/or muscle atrophy in a proximal to distal distribution. Neurogenic muscle abnormalities are characterized by MU inhomogeneity.

Correlations and Comparisons
----------------------------

For assessment of convergent validity, we correlated SARA~GAIT/POSTURE~ ([@B27]) with the scores from: ASMK (dynamic balance), PBS (static balance), GMFCS-E&R, AS, SARA~KINETIC~, and SARA~TOTAL~. For the assessment of discriminant validity, we correlated SARA~GAIT/POSTURE~ sub-scale scores with MF Z-scores. The correlations between SARA~GAIT/POSTURE~ scores and MF Z-scores were subsequently stratified for EOA subgroups with and without comorbid myopathy. To evaluate the potential influence by myopathy and myoclonus on the SARA~GAIT/POSTURE~ scores, we calculated the relative contribution of SARA~GAIT/POSTURE~ to the total SARA scores (i.e., SARA~GAIT/POSTURE~ %sub-score = \[median gait score/median total score\] × 100%), and we compared outcomes between myopathic versus non-myopathic and myoclonic versus non-myoclonic subgroups. For further insight, we also compared the SARA~KINETIC~ sub-score percentages (i.e., SARA~KINETIC~ %sub-score = \[median kinetic score/median total score\] × 100%) between all subgroups.

Statistical Analysis
--------------------

We performed statistical analysis using SPSS statistics 22.0. We determined normality of age, time differences between assessments, median SARA scores, ASMK scores, PBS scores, GFMCS-E&R scores, AS scores and MF z-scores both graphically and by the Shapiro--Wilk test. Correlation results were interpreted by the Evans criteria \[\<0.20 very weak; 0.2 to 0.39 weak; 0.40 to 0.59 moderate; 0.6 to 0.79 strong, and 0.8 to 1 as very strong ([@B11])\]. All statistical tests were two-sided. *p*-values \<0.05 were considered as statistically significant. We applied the Bonferroni correction to adjust the *p*-value for multiple comparisons on the same data.

Results
=======

Scale Descriptives and Inter-Observer Agreement
-----------------------------------------------

For descriptives of SARA, ASMK, PBS, GMFCS-E&R, and MF scores, see **Table [2](#T2){ref-type="table"}**. The included patients revealed a binary distribution of ASMK scores (ASMK scores 1 and 3), corresponding with ambulant and non-ambulant function, respectively. There was no association between cross-sectional SARA scores and age or disease duration (Spearman's Rho, *r*~s~ = 0.110; *p* = 0.58; and *r*~s~ = -0.108; *p* = 0.59, respectively). For missing data, see Appendix A. The inter-observer agreement (ICC) of SARA~GAIT/POSTURE~, SARA~TOTAL~ and SARA~KINETIC~ was high (0.97; 0.97; and 0.88, respectively).

###### 

Rating scale scores per EOA group.

                          Total group (*n* = 28)   EOA~MY\ OPATHIC~ (*n* = 11)   EOA~NON-MY\ OP~ (*n* = 17)   *p*-value   EOA~MY\ OCL~ (*n* = 4)   EOA~NON-MY\ OCL~ (*n* = 24)   *p*-value
  ----------------------- ------------------------ ----------------------------- ---------------------------- ----------- ------------------------ ----------------------------- -----------
  **SARA scores**                                                                                                                                                                
  Total                                                                                                                                                                          
  Median (p25--p75)       14.5 (9.1--25.6)         27 (14.8--30.5)               11 (8.5--18)                 0.022^∗^    13.5 (10.1--18.8)        15.1 (8.7--27.8)              0.694
  Min--max                5--34.5                  5.3--34.5                     5--29.8                                  9--20.5                  5--34.5                       
  **Gait/posture**                                                                                                                                                               
  Median (p25--p75)       6 (4--14.5)              15 (5--18)                    5 (3.3--6.5)                 0.004^∗∗^   5 (3.3--6.8)             6 (4--15)                     0.306
  Min--max                3--18                    4--18                         3--15                                    3--7                     3--18                         
  **Kinetic\#**                                                                                                                                                                  
  Median (p25--p75)       5.3 (3.6--9.2)           8 (4.3--10)                   5 (3.3--8)                   0.144       6 (4.6--10.4)            5.3 (3.5--9.2)                0.469
  Min--max                1.5--11.5                1.5--10.5                     1.5--11.5                                4.5--11.5                1.5--10.5                     
  **ASMK scores**                                                                                                                                                                
  Median (p25--p75)       1 (1--3)                 3 (1--3)                      1 (1--1)                     0.009^∗∗^   1 (1--1)                 1 (1--3)                      0.117
  Min--max                1--3                     1--3                          1--3                                     1--1                     1--3                          
  **PBS scores**                                                                                                                                                                 
  Median (p25--p75)       42 (4--50)               3.5 (0--43.1)                 45 (25.3--50.4)              0.005^∗∗^   43.8 (34.6--48.8)        32.3 (3.8--50)                0.476
  Min--max                0--55                    0--50                         4--55                                    32--50                   0--55                         
  **GMFCS-E&R**                                                                                                                                                                  
  Median (p25--p75)       1 (1--3)                 4 (2--4)                      1 (1--2)                     0.000^∗∗^   1,5 (1--2)               2 (1--4)                      0.243
  Min--max                1--5                     2--5                          1--4                                     1--2                     1--5                          
  **Archimedes spiral**                                                                                                                                                          
  Median (p25--p75)       1.5 (1--2.9)             2 (0.8--3)                    1 (1--2.9)                   0.606       2.3 (1.3--3.6)           1 (1--2.8)                    0.279
  Min--max                0--4                     0--4                          0--4                                     1--4                     0--4                          
  **MF (z-scores)**                                                                                                                                                              
  Median (p25--p75)       -1.2 (-3.5 to -0.4)      -3.2 (-4.8 to -1.3)           -0.6 (-1.3 to -0.2)          0.004^∗∗^   -0.6 (-1.9 to -0.1)      -1.3 (-4.2 to -0.5)           0.245
  Min--max                -5.9 to 0.4              -5.9 to -0.7                  -4.5 to 0.4                              -2.2 to -0.1             -5.9 to 0.4                   
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Convergent Validity: The Association between SARA Scores, Ataxia Severity Measurement Scale (ASMK), Balance Performance (PBS), Gross Motor Functional Classification Scale (GMFCS-E&R), and Archimedes Spiral (AS)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SARA~GAIT/POSTURE~ and SARA~TOTAL~ scores were (very) strongly associated with ASMK, PBS, GMFCS-E&R, SARA~KINETIC~, and AS scores; see **Table [3](#T3){ref-type="table"}** and **Figure [1](#F1){ref-type="fig"}**. For comparison of SARA scores between the ambulant subgroup (AMSK score 1) and the non-ambulant subgroup (AMSK score 3), see Supplementary Table [II](#SM1){ref-type="supplementary-material"}. SARA~GAIT/POSTURE~ sub-analysis for active balance (SARA~WALKING~) and passive balance (SARA~STANCE~/~SITTING~) revealed high correlations: (1) between SARA~WALKING~ items and ASMK scores, and (2) between SARA~STANCE~/~SITTING~ and PBS scores (Spearman's Rho: *r*~s~ = 0.867 and *r*~s~ = 0.917, respectively; *p* \< 0.001). SARA~GAIT/POSTURE~ was also correlated with SARA~KINETIC~ (kinetic function of the upper *and* lower limbs; *r*~s~ = 0.726; *p* \< 0.001) and with AS (kinetic function of the upper limbs; *r*~s~ = 0.609; *p* = 0.002). See **Table [3](#T3){ref-type="table"}** and **Figure [1](#F1){ref-type="fig"}**.

###### 

Correlations between SARA scores and other measurements of coordination.

                       SARA~GAIT/POSTURE~   SARA~TOTAL~   ASMK        PBS         GMFCS-E&R   SARA~KINETIC~^\#^   AS
  -------------------- -------------------- ------------- ----------- ----------- ----------- ------------------- -----------
  SARA~GAIT/POSTURE~   \-                   0.935ˆ\*      0.815ˆ\*    -0.943ˆ\*   -0.862ˆ\*   0.726ˆ\*            0.609ˆ\*
  SARA~TOTAL~          0.935ˆ\*             \-            0.772ˆ\*    -0.911ˆ\*   0.767ˆ\*    0.887ˆ\*            0.805ˆ\*
  ASMK                 0.815ˆ\*             0.772ˆ\*      \-          -0.817ˆ\*   0.848ˆ\*    0.474               0.489
  PBS                  -0.943ˆ\*            -0.911ˆ\*     -0.817ˆ\*   \-          -0.870ˆ\*   -0.685ˆ\*           -0.640ˆ\*
  GMFCS-E&R            -0.862ˆ\*            0.767ˆ\*      0.848ˆ\*    -0.870ˆ\*   \-          0.510               0.461
  SARA~KINETIC~^\#^    0.726ˆ\*             0.887ˆ\*      0.474       -0.685ˆ\*   0.510       \-                  0.846ˆ\*
  AS                   0.609ˆ\*             0.805ˆ\*      0.489       -0.640ˆ\*   0.461       0.846ˆ\*            \-
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, SARA gait and posture sub-scales; ASMK, Ataxia Severity Measurement according to Klockgether; PBS, Pediatric Balance Scale; GMFCS-E&R, Gross Motor Function Classification Scale -- extended and revised version; AS, Archimedes Spiral; \# = Scores are normally distributed; values represent Spearmans Rho;
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correlations are considered statistically significant with p ≤ 0.002 (Bonferroni correction for 21 comparisons). SARA
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correlated strongly with other parameters for coordination measurement.

![Correlation between SARA~GAIT/POSTURE~ sub-scores and ASMK, PBS scores, GMFCS-E&R, SARA~KINETIC~, and AS. The x-axis indicates ASMK scores **(A)**, PBS scores **(B)**, GMFCS-E&R classification **(C)**, SARA~KINETIC~ scores **(D)**, AS scores **(E)**. The y-axis indicates the SARA~GAIT/POSTURE~ scores **(A--E)**. SARA~GAIT/POSTURE~ scores were associated with ASMK, PBS scores, GMFCS-E&R, SARA~KINETIC~, and AS scores. SARA, Scale for Assessment and Rating of Ataxia; ASMK, Ataxia Severity Measurement according to Klockgether; PBS, Pediatric Balance Scale; GMFCS-E&R, Gross Motor Function Classification Scale-the extended and revised version; AS, Archimedes Spiral.](fnhum-11-00605-g001){#F1}

Discriminant Validity
---------------------

\(a\) Association between SARA scores and muscle force

In the *total EOA group*, SARA~GAIT/POSTURE~ and SARA~TOTAL~ revealed strong correlations with muscle weakness of the lower extremities (MF~LE~) and proximal muscles (MF~PROX)~ (MF~LE~ and MF~PROX~). In the 'myopathic' subgroup, SARA~GAIT/POSTURE~ and SARA~TOTAL~ revealed very strong correlations with muscle weakness of the lower extremities. For all *r*-values, see **Table [4](#T4){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**. In the myopathic subgroup, we controlled whether dynamometry and MU assessments corresponded with myopathic pathology (see **Table [5](#T5){ref-type="table"}**). MU analysis revealed pure myopathic changes in 60% and combined myopathic/neurogenic changes in 30%. In the non-myopathic subgroup, the above mentioned correlations with muscle weakness were absent. This group revealed one child with neuropathic alterations and substantial muscle weakness, revealing a similar association between SARA~GAIT/POSTURE~ scores and muscle weakness as the myopathic group. For subgroup correlations, see **Table [4](#T4){ref-type="table"}** and **Figures [2A](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**.

###### 

Correlations between SARA scores and muscle force.

                                   Total group   EOA~MY\ OPATHIC~   EOA~NON-MY\ OP~
  -------------------------------- ------------- ------------------ -----------------
  SARA~Total~-MF~Total~^∧^         -0.719^∗∗^    -0.903^∗∗^         -0.308
  SARA~GAIT/POSTURE~-MF~LE~^∧^     -0.724^∗∗^    -0.882^∗^          -0.320
  SARA~GAIT/POSTURE~-MF~Prox~^∧^   -0.690^∗∗^    -0.894^∗∗^         -0.248
  SARA~KINETIC~^\#^-MF~UE~^\#^     -0.574^∗^     -0.619             -0.410
  SARA~KINETIC~^\#^ -MF~Prox~^∧^   -0.516        -0.564             -0.293
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![Correlation between SARA scores and MF in EOA patients. **(A,D)** Represent outcome data in all patients. **(B,E)** Represent outcome data in non-myopathic patients. **(C,F)** Represent outcome data in myopathic patients. Orange markers represent patients with abnormal MU characteristics (by expert opinion). **(A--C)** The x-axis indicates MF~TOTAL~ z-scores; the y-axis indicates SARA~TOTAL~ scores. **(D--F)** The x-axis indicates MF~LE~ z-scores; the y-axis indicates SARA~GAIT/POSTURE~ scores. *r*~s~ values are presented in case of significant correlations. SARA, Scale for Assessment and Rating of Ataxia; MF, muscle force; LE, lower extremities. In heterogeneous EOA patients, the association between SARA scores and MF is attributed to outcomes of myopathic patients.](fnhum-11-00605-g002){#F2}

###### 

Muscle Ultrasound Abnormalities in myopathic and non-myopathic patients.

                                                                         EOA~MY\ OPATHIC~ (*n* = 10)   EOA~NON-MY\ OP~ (*n* = 14)
  ---------------------------------------------------------------------- ----------------------------- ----------------------------
  Myopathic muscle abnormalities                                         *n* = 6 (60%)                 
  Neurogenic muscle abnormalities                                                                      *n* = 4 (29%)^∗^
  Combined myopathic/neurogenic muscle abnormalities None of the above   *n* = 3 (30%) *n* = 1 (10%)   *n* = 10 (71%)

EOA

MYOPATHIC

, EOA with reported comorbid myopathy; EOA

NON-MYOP

, EOA with absent comorbid myopathy (EOA

MYOCLONUS

\+ EOA

OTHER

);

∗

corresponding diagnoses were: ataxia telangiectasia (n = 1). Nieman--Pick's disease (n = 1) and unknown (n = 2).

\(b\) Association between SARA scores, myopathy and myoclonus

Comparing EOA subgroups, revealed the highest %contribution of the SARA~GAIT/POSTURE~ to the SARA~TOTAL~ (i.e., SARA~GAIT/POSTURE~/SARA~TOTAL~ × 100%) in the myopathic subgroup (Mann--Whitney *U*, *p* = 0.038), see **Figure [3](#F3){ref-type="fig"}**. Comparing the %contribution of the SARA~GAIT/POSTURE~ to SARA~TOTAL~ between myoclonic versus non-myoclonic subgroups, revealed a significantly lower %contribution of the SARA~GAIT/POSTURE~ in the myoclonic subgroup (Mann--Whitney *U*, *p* = 0.018, see **Figure [3](#F3){ref-type="fig"}**). Conversely, we observed the highest %contribution of the SARA~KINETIC~ to SARA~TOTAL~ (i.e., SARA~KINETIC~/SARA~TOTAL~ × 100%) in the myoclonic subgroup (Mann--Whitney *U*, *p* = 0.028), see **Figure [3](#F3){ref-type="fig"}**. For subgroup comparisons between myoclonic, myopathic, and other (non-myoclonic and non-myopathic), see **Figure [4](#F4){ref-type="fig"}**.

![Influence of myopathy and myoclonus on SARA %sub-scores. The x-axis represents the EOA phenotypes (myopathic versus non-myopathic, and myoclonic versus non-myoclonic). The y-axis represents the median SARA~GAIT/POSTURE~ %sub-score (i.e., \[SARA~GAIT/POSTURE~ sub-score/median total score\] × 100%, **A,C**); and the median SARA~KINETIC~ %sub-score (i.e., \[median SARA~KINETIC~ score/median total score\] × 100%, **B,D**). Boxes represent lower quartile, median and upper quartile; whiskers represent the minimum and maximum relative %sub-score. SARA~GAIT/POSTURE~, SARA gait and posture sub-score; SARA~KINETIC~, SARA kinetic sub-score. Comparing the %contribution of the SARA~GAIT/POSTURE~ to SARA~TOTAL~ between myopathic versus non-myopathic subgroups, revealed a significantly higher %contribution of the SARA~GAIT/POSTURE~ in the myopathic subgroup **(A)**, whereas the %contribution of the SARA~KINETIC~ was not significantly different between both groups **(B)**. Comparing the %contribution of the SARA~KINETIC~ to SARA~TOTAL~ between myoclonic versus non-myoclonic subgroups, revealed a significantly higher %contribution in the myoclonic subgroup **(C)**, whereas the %contribution of the SARA~GAIT/POSTURE~ revealed a significantly lower %contribution in the myoclonic subgroup **(D)**.](fnhum-11-00605-g003){#F3}

![Comparison of relative SARA %sub-scores between co-morbidity subgroups. The x-axis represents the EOA phenotypes \[myopathic, myoclonic, and other (non-myopathic and non-myoclonic)\]. The y-axis represents: **(A)** the median SARA~GAIT~ %sub-score (i.e., \[SARA~GAIT~ score/median total score\] × 100%) and **(B)** the median SARA~KINETIC~ %sub-score (i.e., \[median SARA~KINETIC~ score/median total score\] × 100%). Boxes represent lower quartile, median and upper quartile; whiskers represent the minimum and maximum relative %-sub-score. SARA~GAIT/POSTURE,~ SARA gait and posture sub-score; SARA~KINETIC~, SARA kinetic sub-score. Myoclonic EOA phenotypes reveal a relatively smaller %SARA~GAIT~ than %SARA~KINETIC~ sub-scores compared to the other subgroups.](fnhum-11-00605-g004){#F4}

Discussion
==========

In children and young adults with EOA, we aimed to investigate the construct validity of SARA~GAIT/POSTURE~ sub-scores. SARA~GAIT/POSTURE~ sub-scores revealed a high inter-observer agreement (ICC) and were strongly associated with other quantitative scales for coordinative motor function, such as: active and static balance (ASMK, PBS), kinetic limb performances (SARA~KINETIC~, AS) and total ataxia scores (SARA~TOTAL~). Furthermore, we also observed a strong correlation between SARA~GAIT/POSTURE~ sub-scores and the classification levels of the GMFCS (E&R), which is originally designed for the assessment of functional motility in children with cerebral palsy ([@B20], [@B21]). The discriminant validity of the SARA~GAIT/POSTURE~ subscale between the measurement of ataxia and co-morbidity factors (muscle weakness and myoclonus) was incomplete. In children and young adults with EOA, we conclude that SARA~GAIT/POSTURE~ scores are reliable. However, SARA~GAIT/POSTURE~ parameters discriminate insufficiently between the influence by ataxia and muscle weakness. This implicates that gait and posture scores should be interpreted in homogeneous EOA subgroups that take comorbid muscle weakness into account.

In previous EOA studies, we have shown that tools for the assessment of ataxic gait may contribute to the early recognition of indisputable EOA in young patients ([@B19]). Furthermore, well-validated clinical biomarkers for EOA gait and posture assessment are useful for the evaluation of pediatric treatment strategies, targeting at the training of core-muscle function ([@B33]; [@B25]). In the present study, we observed an excellent inter-observer agreement (ICC) on SARA~GAIT/POSTURE~ sub-scores, which was in the same range as SARA~TOTAL~ and SARA~KINETIC~ sub-scores. These SARA~TOTAL~ outcomes are in agreement with previously published ICC data in adult patients with predominantly AOA phenotypes ([@B27]).

We determined convergent validity of SARA~GAIT/POSTURE~ sub-scores under the premise that all ataxic gait parameters for walking, standing, and balancing would depend on the same integrated cerebellar processing of sensory, visual, and vestibular signals ([@B31]) with upper- and lower- limb and trunk motor performances ([@B28]; [@B9]). We thus hypothesized that the construct validity of SARA~GAIT/POSTURE~ could be reflected by the association with other coordinative motor function tests requiring cerebellar integration of multimodal signals. Accordingly, we observed that SARA~GAIT/POSTURE~ sub-scores were strongly associated with the tested parameters for coordinated motor function. The SARA~GAIT/POSTURE~ items for active and passive balance were strongly related with ASMK and PBS scores and also with GFMCS classifications, implicating that the closely associated test objectives have a functional significance. Furthermore, SARA~GAIT/POSTURE~ scores were also correlated with kinetic functions of the upper and lower extremities, which can be understood by the fact that gait kinetics (including arm swing, turning, balance and tandem -stance and -gait performances) also require accurate limb kinetics. Finally, SARA~GAIT/POSTURE~ scores appeared strongly associated with SARA~TOTAL~ scores. Although correlated, SARA~GAIT/POSTURE~ and AS scores revealed the lowest correlation. In perspective of the differences in tested cerebellar domains (vermis versus hemispheres) and the differences regarding motor function tasks (gross versus fine motor function tasks), the lower correlation is in accordance with our expectations. As focal cerebellar damage was excluded from the present study group inclusion, one could attribute the above mentioned correlations between different cerebellar domains and/or motor function tasks to global functional pathology of the cerebellum. In young, ataxic EOA patients without focal cerebellar lesions, these results may thus implicate that SARA~GAIT/POSTURE~ scores can provide a global impression of the total ataxia-severity. When ambulant EOA children without focal lesions are too young (\<4 years of age) or lack the motivation and/or concentration to complete all SARA motor task performances, SARA~GAIT/POSTURE~ parameters could theoretically provide a fast and easy biomarker to estimate ataxia-progression. Altogether, in children and young adults with distinct EOA features, SARA~GAIT/POSTURE~ can reliably measure 'ataxic' gait severity and may also provide a global impression of the total ataxia severity.

We obtained the above mentioned results under the premise that SARA and other coordination scales measure the same objective. However, as already stated for the AS, this is not necessarily correct, as the other biomarkers (such as for active and passive balance, and kinetic function) may measure more than the objective 'ataxia,' alone. This implicates that other factors than ataxia could theoretically influence SARA~GAIT/POSTURE~ scores. For instance, in previous studies, we have shown that the age of the child (i.e., cerebellar maturation) has an influence on SARA scores ([@B29]; [@B5]). Although mean age-related effects are comparatively small in relation to pathologic SARA scores in ataxic patients, the Childhood Ataxia and Cerebellar Group of the European Pediatric Neurology Society has recently shown that children younger than 8 years of life can also reveal considerable variation in SARA~TOTAL~ scores, which may affect the interpretation of the longitudinal scores ([@B18]). However, as the variation of SARA~GAIT/POSTURE~ sub-scores in young children appeared much smaller ([@B18]), one could use the SARA~GAIT/POSTURE~ sub-scale as an internal control to discriminate between physiological age-related and ataxia effects on the SARA~TOTAL~ scores. To elucidate the SARA~GAIT/POSTURE~ test construct, we also investigated the potential effects of co-morbidity factors on the SARA~GAIT/POSTURE~ sub-scores. SARA~GAIT/POSTURE~ and SARA~TOTAL~ scores revealed an incomplete discriminant validity between ataxia and comorbid 'muscle weakness.' Although this does not automatically implicate a causal relationship, absence of a relationship between muscle weakness and SARA~GAIT/POSTURE~ and SARA~TOTAL~ scores cannot be assumed, either. For instance, when the child has difficulties to raise an arm against gravity, or when the child has just sufficient MF to walk with support, muscle weakness is likely to affect the scores. Furthermore, in case of limiting muscle weakness to execute the SARA rating scale task, maximal scores should be given. In the latter case, ataxia itself has not determined the score, but limiting muscle weakness instead. This implicates that the discriminant validity of SARA ~GAIT/POSTURE~ sub-scores between muscle weakness and ataxia is incomplete.

Analyzing the patient inclusion of the myopathic EOA cohort, revealed a majority of patients with FA. This underpins our previously reported study data on the association between muscle weakness and ataxia scores in FA children ([@B30]). Interestingly, in another FA cohort, this association between SARA scores and muscle weakness was not reported ([@B8]). However, in the latter study, MF Z-scores were not available, implicating that exact correlations cannot be made. Furthermore, one should be aware that correlations between muscle weakness and SARA scores would require patient sub-groups with sufficient variety in MF. For example, in homogeneous EOA groups with normal physiological muscle strength, the influence by muscle weakness on SARA scores would not be addressed. Similarly, in homogeneous EOA groups with severely progressed muscle weakness (represented by non-ambulant patients), plateauing SARA scores would also obscure an association with muscle weakness. These results implicate that it is advisable to obtain SARA~GAIT/POSTURE~ scores in homogeneous EOA subgroups and to stratify outcomes for substantial variations in muscle weakness. Finally, we investigated the EOA influence of comorbid myoclonus on SARA~GAIT/POSTURE~ sub-scores. In the comorbid myoclonus subgroup, the percentage (%) contribution of SARA~GAIT/POSTURE~ to SARA~TOTAL~ scores was low compared to non-myoclonus subgroup, reflecting a negative effect. Interestingly, the percentage (%) contribution of SARA~KINETIC~ to SARA~TOTAL~ scores was high in the comorbid myoclonus subgroup, compared to non-myoclonus subgroup, implicating a predominant effect of comorbid myoclonus on SARA~KINETIC~, instead of SARA~GAIT/POSTURE~ scores. As myoclonic jerks in GOSR2 patients may start at the upper extremities and increase during intended kinetic limb movements, these findings are understandable.

We are aware that this study has several limitations. First, the EOA patients fulfilling the requirements for patient inclusion are rare, implicating that the number of patients was limited. However, as the present data are obtained in a specialized movement disorder center over a study period of 5 years (with an inclusion rate of 100%), investigation of a larger patient cohort will not easily be accomplished. Second, we realize that statistically significant correlations do not necessarily implicate causality ([@B12]). But, as significant correlations between SARA~GAIT/POSTURE~ sub-scores and MF were consistently absent in patients without MF loss, our findings do not reject causality, either. Third, to avoid an unacceptable test burden and exhaustion for the patients, we planned different tests during successive medical visits to our outpatient clinic (see Supplementary Table [I](#SM1){ref-type="supplementary-material"}). However, as latent time intervals between tests would only exert a negative influence on the correlations, the positive inter-correlations between SARA~GAIT/POSTURE~ and other ataxia biomarkers cannot be attributed to it. Fourth, we cannot exclude that other, yet unexplored confounders may also exist (such as neuropathy, concentration, behavior, and tiredness). Altogether, in the perspective of the presented findings, we conclude that SARA~GAIT/POSTURE~ scores are associated with MF loss. In EOA patients with comorbid myopathy, it appears prudent to interpret SARA~GAIT/POSTURE~ scores for the severity of muscle weakness.

Conclusion
==========

The inter-observer agreement and convergent validity of SARA~GAIT/POSTURE~ scores in EOA patients are high, implicating the reliability of the scores. Regarding the incomplete discriminant validity of the scores, it is advisable to interpret SARA~GAIT/POSTURE~ scores for comorbid muscle weakness.
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Click here for additional data file.

AOA

:   adult onset ataxia

AS

:   Archimedes Spiral

ASMK

:   Ataxia Severity Measurement according to Klockgether

EOA

:   early onset ataxia (starting before the 25th year of life)

FA

:   Friedreich's ataxia

GMFCS-E&R

:   Gross Motor Function Classification Scale- extended and revised version

ICARS

:   International Cooperative Ataxia Rating Scale

MF

:   muscle force

MF~LE~

:   MF z-score of lower extremities

MF~Prox~

:   MF z-scores of proximal muscles

MF~TOTAL~

:   total MF z-score

MF~UE~

:   MF z-score of upper extremities

MU

:   muscle ultrasound

PBS

:   Pediatric Balance Scale

SARA

:   Scale for Assessment and Rating of Ataxia

SARA~TOTAL~

:   summed total SARA score

SARA~GAIT/POSTURE~

:   the summed SARA sub-scores for gait, stance and sitting

SARA~KINETIC~

:   SARA kinetic sub-score
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